- Lumacaftor/ivacaftor, sold
under the
brand name
Orkambi among others, is a
combination of
lumacaftor and
ivacaftor used to
treat people with
cystic fibrosis...
- F508del mutation. The
combination drug is
marketed under the
tradename Orkambi. On 28
March 2017,
Vertex announced Phase 3 data from a dual combination...
- 1358/dot.2013.49.4.1940984. PMID 23616952. "
Orkambi-
lumacaftor and
ivacaftor tablet, film
coated Orkambi-
lumacaftor and
ivacaftor granule prescribing...
- pill with ivacaftor; the combination, lumacaftor/ivacaftor (brand name
Orkambi), is used to
treat people with
cystic fibrosis who are
homozygous for the...
- to 2020.
Under his leadership,
Vertex developed and
launched Kalydeco,
Orkambi,
Symdeko and
Trikafta – the
first medicines to
treat the
underlying cause...
- cases. Grooten****s also led the
Vertex team to
subsequent discovery of
Orkambi, the
combination of
Ivacaftor and Lumacaftor(VX-809),
approved to treat...
-
minimum unit
pricing Antimicrobial resistance inquiry Availability of
Orkambi on the NHS
Brexit – medicines,
medical devices and
substances of human...
-
Vehicle insurance in the
United Kingdom Debate video Hansard 19/3/2018 Make
Orkambi available on the NHS for
people with
Cystic Fibrosis Lumacaftor/ivacaftor...
